Catalyst Metals And 2 Australian Growth Stocks To Watch

Oil parked above $110 a barrel, and the International Energy Agency warns energy markets are unlikely to settle next year. That kind of prolonged strain often rewards businesses that can grow earnings from a strong financial base rather than rely on cheap capital or smooth conditions. This article walks through three Australian growth stocks from a high quality screener that flags companies with robust finances and solid earnings potential.

The three stocks highlighted here offer a compelling starting point if you want exposure to healthy high growth potential businesses backed by acceptable balance sheets. However, if you want the strongest names, these 33 best high growth potential stocks are at the top of the list.

Catalyst Metals (ASX:CYL)

Overview: Catalyst Metals is a Perth based gold miner and explorer focused on developing the Plutonic Gold Belt projects in Western Australia.

Operations: The business generates about A$629 million of revenue from Western Australia, with total A$632 million earned entirely within Australia.

Market Cap: A$1.45b

Catalyst Metals plugs neatly into the Healthy high growth potential theme because its Plutonic Gold Belt projects link near term production growth with an existing earnings base that already produced A$631.94 million of sales and A$171.12 million of net income in 2026. That combination of cash generation and development potential may be appealing, depending on how one unseen pressure shapes future mining costs and margins.

If that pressure matters for you, start with the 5 key rewards and 1 important major warning sign to see how Catalyst Metals’ growth story compares with its key pressure points.

Neuren Pharmaceuticals (ASX:NEU)

Overview: Neuren Pharmaceuticals develops and commercializes treatments for rare neurological disorders, with DAYBUE and NNZ-2591 anchoring its high growth potential profile.

Operations: Neuren Pharmaceuticals generates about A$69.5 million from commercial products, with all reported revenue currently coming from the United States.

Market Cap: A$2.50b

Neuren Pharmaceuticals fits the Healthy high growth potential theme because its approved Rett syndrome medicine gives it commercial footing. In addition, a rare disease pipeline provides further opportunities to expand future earnings.

"The expectation of increased diagnosed population and patient uptake of DAYBUE in the U.S. indicates potential revenue growth with more patients getting access to the drug."

Future returns for investors may depend on how one key partner driven revenue source affects margins, cash generation, and growth durability.

That partner risk is only half the story, and the full narrative for Neuren Pharmaceuticals shows how Neuren Pharmaceuticals balances accelerating opportunities with the pressures behind those royalties.

Netwealth Group (ASX:NWL)

Overview: Netwealth Group runs an Australian wealth-management platform where superannuation, investor-directed portfolios, and managed accounts generate scalable, fee-based revenue growth.

Operations: Netwealth Group earns A$389.7 million from platform operations, all generated in Australia through its wealth-management services.

Market Cap: A$4.0 billion

Netwealth Group matters for the Healthy high growth potential theme because its wealth platform ties expected earnings expansion directly to fee-based services rather than one-off bets.

"Netwealth's continued investment in best-in-class digital experience, platform functionality, and data analytics aligns with the ongoing digitisation of financial services and increasing regulatory focus on transparency, positioning the company to capture greater adviser and client net inflows, bolster revenue growth, and strengthen platform stickiness."

Future earnings momentum may hinge on how one unresolved pressure shapes the balance between rising technology investment and long term platform margins.

That margin trade off is exactly what the full narrative for Netwealth Group unpacks, revealing where Netwealth Group might be quietly accelerating or where cost pressure could be masking platform strength.

Curious About The Next Alternatives?

Fresh ideas move first. Stocks can shift from quiet to breakout while the crowd is still looking elsewhere. Scan these focused shortlists while the data still matters and get in early.

• Target resilient cash generators and stress test your downside using a curated list of solid balance sheet and fundamentals (12 results) before sentiment shifts and quality gets fully priced.
• Ride structural themes in electricity and grid upgrades by reviewing a hand built set of 43 power grid technology and infrastructure stocks while many investors are still looking away.
• Back potential income workhorses and track payout reliability through a filtered group of 5 dividend fortresses before yields drop and attention floods in.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com